Core Insights - Organoid technology is a disruptive breakthrough in life sciences, rapidly transitioning from laboratory research to clinical applications, providing new tools for disease mechanism research, drug screening, and personalized treatment [2] - The integration of organoids with automation technology is accelerating the translation of research outcomes into practical applications in precision medicine [2] Event Details - An online seminar titled "AI Automation Solutions Accelerating Organoid Research and Drug Development" will be held on May 14, 2025, from 14:00 to 15:30, organized by Opentrons in collaboration with ISCO [2] - The seminar will feature academic scholars, technical experts, and industry pioneers focusing on academic breakthroughs in organoid technology and automation solutions [2] Speaker Information - Lin Xinhua, Executive Director of the Guangdong-Hong Kong-Macao Greater Bay Area Precision Medicine Research Institute, will present on the application of organoids in precision medicine [4] - Lin Delin, Senior Application Technical Support Engineer at Opentrons, will discuss Opentrons' organoid automation solutions [4][8] - Gao Zhengliang, a researcher at Shanghai University School of Medicine, will cover the application of organoids in brain development and diseases [4][11] Additional Engagement - The live event will include interactive segments with exciting prize draws for participants who engage through comments [12][16]

Core Viewpoint - The company, Yinos, is a leading contract research organization (CRO) in the non-clinical safety evaluation sector, providing comprehensive research services that align with both domestic and international standards, and has recently passed a GLP inspection by the FDA, enhancing its international service capabilities [25][26]. Company Overview - Yinos specializes in non-clinical research services for biopharmaceuticals, being one of the earliest companies in China to obtain GLP certifications from NMPA, OECD, and FDA, thus aligning with international standards [3][4]. - The company has a modern facility of nearly 60,000 square meters and a research team of over 1,000, with locations in Shanghai, Nantong, Shenzhen, Huangshan, and San Francisco [4]. - As of December 31, 2024, Yinos has served over 900 pharmaceutical companies and research institutions, contributing to numerous successful drug development cases [4][18]. Financial Performance - In the reporting period, Yinos achieved a revenue of RMB 1,141.67 million, representing a year-on-year growth of 9.94%, while the net profit attributable to shareholders decreased by 24% to RMB 147.78 million [23]. - The proposed profit distribution plan includes a cash dividend of RMB 3.2 per 10 shares, totaling RMB 45.11 million, which accounts for 30.53% of the net profit for the year [1]. Industry Context - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2026, with the market size expected to exceed USD 147.7 billion by 2030 [11]. - In China, the CRO service market is estimated to reach RMB 848.2 billion in 2023, with a projected CAGR of 9.9% from 2023 to 2026 [12]. - The industry is supported by government policies aimed at enhancing drug research and development capabilities, which is expected to drive long-term growth in the CRO sector [13][14]. Technological Advancements - Yinos is investing in artificial intelligence (AI) applications in non-clinical research, aiming to enhance efficiency and reduce costs in drug development processes [19]. - The company is also exploring organoid technology for drug screening and toxicity testing, which is gaining traction in the pharmaceutical research field [19][20]. Strategic Positioning - Yinos has established strong partnerships with leading pharmaceutical companies, positioning itself as a strategic partner in the innovative drug development process [18][21]. - The company is expanding its international presence, having established a subsidiary in the United States to enhance its global market share [22].